

RECEIVED
CENTRAL FAX CENTER

MAY 23 2005

Law Offices of

SENNIGER POWERS

One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102Telephone (314) 231-5400
Facsimile (314) 231-4342

FACSIMILE TRANSMITTAL COVER SHEET

DATE: May 23, 2005 ATTORNEY DOCKET NUMBER: PHA 4142.2 (2891/3)
PTO FACSIMILE NUMBER: (703) 872-9306
PLEASE DELIVER THIS FACSIMILE TO: Examiner Jon D. Epperson Ph.D.
THIS FACSIMILE IS BEING SENT BY: Kathleen M. Petrillo
NUMBER OF PAGES: 31 INCLUDING COVER SHEET
TIME SENT: 5:39pm OPERATOR'S NAME Lori Macke

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Lori Macke
Typed or printed name of person signing certification
Lori Macke
Signature
May 23, 2005
Date

Type of paper transmitted: Response to Notice of Non-Compliant
Amendment and Copy of Fee Transmittal and Check from Amendment F
Applicant's Name: Peter C. Isakson et al.
Serial No. (Control No.): 10/038,080 Examiner: Jon D. Epperson
Filing Date: January 3, 2002 Art Unit: 1639 Confirmation No.: 7358
Application Title: TREATMENT OF INFLAMMATION AND INFLAMMATION-
RELATED DISORDERS WITH A COMBINATION OF A
CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B4
RECEPTOR ANTAGONIST

IF YOU DO NOT RECEIVE ALL PAGES CLEARLY, CALL BACK AS SOON AS POSSIBLE. CONFIRMING NUMBER IS (314) 231-5400.

**RECEIVED
CENTRAL FAX CENTER**

MAY 23 2005

**PHA 4142.2 (2891/3)
PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Peter C. Isakson, et al.

Art Unit 1639

Serial No. 10/038,080

Filed January 03, 2002

Confirmation No. 7358

**For TREATMENT OF INFLAMMATION AND INFLAMMATION-RELATED
DISORDERS WITH A COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A
LEUKOTRIENE B4 RECEPTOR ANTAGONIST**

Examiner Jon D. Epperson Ph.D.

May 23, 2005

RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT

TO THE COMMISSIONER FOR PATENTS

SIR:

In response to the Office action dated April 22, 2005, entitled Notice of Non-Compliant Amendment, the following remarks are respectfully submitted:

Listing of the Claims begins on page 2 of this paper.

Remarks begin on page 27 of this paper.

Conclusion begins on page 28.